tiprankstipranks
Advertisement
Advertisement

ZBIO Stock Latest News

Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS Segment
Company AnnouncementsZenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS Segment
2d ago
ZBIO
Zenas BioPharma price target raised to $22 from $21 at Morgan Stanley
PremiumThe Fly
Zenas BioPharma price target raised to $22 from $21 at Morgan Stanley
6d ago
ZBIO
Citi opens ‘upside 30-day catalyst watch’ on Zenas BioPharma
PremiumThe Fly
Citi opens ‘upside 30-day catalyst watch’ on Zenas BioPharma
6d ago
ZBIO
Zenas BioPharma doses first patient in Phase 1 clinical trial of ZB021
PremiumThe Fly
Zenas BioPharma doses first patient in Phase 1 clinical trial of ZB021
7d ago
ZBIO
Zenas BioPharma Highlights Strong Q1 Progress and Financing
PremiumCompany Announcements
Zenas BioPharma Highlights Strong Q1 Progress and Financing
7d ago
8K
ZBIO
Zenas BioPharma reports Q1 EPS ($1.46) vs. (80c) last year
PremiumThe FlyZenas BioPharma reports Q1 EPS ($1.46) vs. (80c) last year
7d ago
ZBIO
Zenas BioPharma, Inc. (ZBIO) Q1 Earnings Cheat Sheet
Premium
Pre-Earnings
Zenas BioPharma, Inc. (ZBIO) Q1 Earnings Cheat Sheet
8d ago
ZBIO
Insiders Are Scooping Up These 2 ‘Strong Buy’ Stocks
Premium
Stock Analysis & Ideas
Insiders Are Scooping Up These 2 ‘Strong Buy’ Stocks
1M ago
NAVN
ZBIO
Zenas BioPharma Raises Capital via Notes and Equity Offering
PremiumCompany Announcements
Zenas BioPharma Raises Capital via Notes and Equity Offering
2M ago
8K
ZBIO
Zenas BioPharma director buys $1.5M in common stock
PremiumThe Fly
Zenas BioPharma director buys $1.5M in common stock
2M ago
ZBIO
Zenas BioPharma 5M share Spot Secondary priced at $20.00
PremiumThe Fly
Zenas BioPharma 5M share Spot Secondary priced at $20.00
2M ago
ZBIO
Closing Bell Movers: Argan jumps 10% on earnings beat
PremiumThe Fly
Closing Bell Movers: Argan jumps 10% on earnings beat
2M ago
U
AGX
Zenas announces common stock, convertible senior notes offerings
PremiumThe FlyZenas announces common stock, convertible senior notes offerings
2M ago
ZBIO
Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis
Premium
Company Announcements
Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis
2M ago
ZBIO
Zenas BioPharma price target raised to $55 from $45 at Guggenheim
Premium
The Fly
Zenas BioPharma price target raised to $55 from $45 at Guggenheim
2M ago
ZBIO
Balanced Near‑Term Outlook for Zenas BioPharma: Promising Obexelimab Pipeline and Strengthened Liquidity Offset by Commercial and Leverage Uncertainties
PremiumRatings
Balanced Near‑Term Outlook for Zenas BioPharma: Promising Obexelimab Pipeline and Strengthened Liquidity Offset by Commercial and Leverage Uncertainties
2M ago
ZBIO
Zenas BioPharma price target raised to $21 from $19 at Morgan Stanley
PremiumThe Fly
Zenas BioPharma price target raised to $21 from $19 at Morgan Stanley
2M ago
ZBIO
Zenas BioPharma: De‑Risked Autoimmune Late‑Stage Assets and Strong Balance Sheet Underpin Buy Rating and $44 Target
PremiumRatings
Zenas BioPharma: De‑Risked Autoimmune Late‑Stage Assets and Strong Balance Sheet Underpin Buy Rating and $44 Target
2M ago
ZBIO
Zenas BioPharma price target lowered to $41 from $43 at Citi
PremiumThe Fly
Zenas BioPharma price target lowered to $41 from $43 at Citi
2M ago
ZBIO
IPO-Related Securities Class Action Poses Ongoing Financial and Operational Risks for Zenas BioPharma
PremiumCompany AnnouncementsIPO-Related Securities Class Action Poses Ongoing Financial and Operational Risks for Zenas BioPharma
2M ago
ZBIO
Morning Movers: National Storage surges following Public Storage buyout
Premium
The Fly
Morning Movers: National Storage surges following Public Storage buyout
2M ago
MU
WW
Zenas BioPharma reports Q4 EPS ($4.54) vs. ($1.26) last year
Premium
The Fly
Zenas BioPharma reports Q4 EPS ($4.54) vs. ($1.26) last year
2M ago
ZBIO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >